



## Immuron to Present at the RedChip Global Online Microcap Conference

**22<sup>nd</sup> October, 2015 – Melbourne, Australia:** Mr Thomas Liquard, CEO of Immuron Limited (ASX: IMC; OTC US: IMROY), is scheduled to present at the RedChip Global Online Microcap Conference on Thursday 22<sup>nd</sup> October, 2015, at 9:30AM US Eastern time. The presentation can be viewed at [www.RedChip.com](http://www.RedChip.com).

A live Q&A session will follow the investor presentation. Investors can pre-submit their questions by visiting <http://www.redchip.com/events/3/global-online-microcap-conference>.

The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change.

As previously announced, Immuron engaged Red Chip for the provision of certain US Investor Relations Services. On 20<sup>th</sup> August 2015 Red Chip released an Analyst Report which attracted significant online and market attention. A copy of this report is available at [www.immuron.com/index.php/download\\_file/-/view/140/](http://www.immuron.com/index.php/download_file/-/view/140/).

### **Contact:**

Thomas Liquard  
Chief Executive Officer  
AUS Ph: +61 (0)3 9824 5254  
Email: [thomasliquard@immuron.com](mailto:thomasliquard@immuron.com)

Jon Cunningham  
RedChip Companies, Inc.  
US Tel: 0011 1-800-RED-CHIP (733-2447), ext. 107  
Email: [info@redchip.com](mailto:info@redchip.com)

### ***About RedChip Companies, Inc.***

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. [www.redchip.com](http://www.redchip.com)

The Immuron logo is located in the top right corner. It consists of the word "Immuron" in a blue, sans-serif font, followed by a circular icon containing a stylized white 'e' shape.

Immuron

# COMPANY PRESENTATION

October 2015

# Forward-Looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.



## Corporate Overview

- **Unique and Leverageable Platform** – Proprietary oral immunotherapy technology targeting microbiome and inflammation with broad utility
- **Attracting Leading Collaborations** – NIH, Renowned experts and institutions
- **Strong Pipeline** – High value indications, with leading competitive profiles
  - **Phase II in NASH (Fatty-Liver Disease)**
    - Targeted End of enrollment: 2Q16; Top Line results: 4Q16 – 1Q17
    - Two unique inflammatory modulating mechanisms: (1) Binds to LPS, (2) Promotes regulatory T-Cell; Restores normal liver function and reverses fibrosis
    - No approved therapy, \$40B market by 2025
  - **C-Difficile program targeting the 3 key infectious cycles (Toxin B, Spores, and Vegetative cells) in pre-clinical stage**
    - Developed in collaboration with world renown C-difficile team at Monash
    - Phase 1/2 start anticipated in 1H2016
- **Generating Growing Revenues** – Travelan™ for Traveler's Diarrhea
- **Significantly Undervalued** – Substantial upside exist for investors

# Investment Highlights

## Immuron Is a Compelling Investment Opportunity...

---

<b>NASH and ASH:</b>	Two Phase II studies in progress with an increasingly alluring potential upside
<b>Travelan:</b>	Revenues growing and positioned to grow further with successful USA launch
<b>Pipeline:</b>	Progressing; potential for multi-billion \$ assets
<b>Cap Profile:</b>	Robust
<b>Financials:</b>	Debt free, cash in the bank until after completion of NASH trial

---

## ... With Significant Room for Valuation Upside NASH Peer Comparables

NASH Peer Comparables					
Company Name	Ticker	Share Price (USD)	Market Cap (USD)	Cash (MRQ, USD)	Total Debt (MRQ, USD)
Intercept Pharmaceuticals Inc	ICPT	\$213.99	\$5,179.M	\$732.3M	\$0.0
Raptor Pharmaceutical Corp	RPTP	\$13.35	\$1,083.8M	\$220.5M	\$117.0M
Genfit SA	GNFT	\$40.08	\$960.2M	\$28.8M	N/A
Enanta Pharmaceuticals Inc	ENTA	\$40.41	\$756.2M	\$154.2M	\$0.4M
Ardelyx Inc	ARDX	\$18.21	\$472.1M	\$141.5M	\$0.0
Galmed Pharmaceuticals Ltd	GLMD	\$9.15	\$101.6M	\$29.9M	\$0.0
MediciNova Inc	MNOV	\$3.60	\$89.6M	\$8.6M	\$0.0
Conatus Pharmaceuticals Inc	CNAT	\$4.15	\$81.8M	\$31.0M	\$1.0M
Viking Therapeutics Inc	VKTX	\$7.31	\$71.5M	\$0.3M	\$1.7M
Galectin Therapeutics Inc	GALT	\$2.70	\$61.5M	\$26.3M	\$1.6M
Islet Sciences Inc	ISLT	\$0.04	\$2.8M	\$0.02M	\$0.05M
	<i>median</i>		\$101.6M	\$29.9M	\$0.2M
	<i>average</i>		\$805.5M	\$124.9M	\$12.2M


## Strong Financial Position:

- Ticker Code: IMC.AX (Australia)
- Share price: (as at 22 October 2015) AUD\$0.51; USD\$0.37
- Shares outstanding: 75M
- Market Cap: AUD\$40M; USD\$29M
- Cash: (as of 30 June 2015) \$3.1M
- Debt: \$0



Immuron

PIPELINE






## Portfolio

- **IMM-124E (anti LPS + adjuvants) for NASH**
- IMM-529 for Clostridium Difficile

# IMM-124E

## Compelling MOA in NASH

### NASH – Pathogenesis




Immuron

### IMM-124E – MOA

#### Unique Properties

- Increased concentration of immunoglobulin (mainly IgG)
- Strong anti-LPS properties, Cross reactive
- Immune-reactive adjuvants that promote regulatory T-Cells that suppress systemic inflammation
- Not absorbed in the blood
- Immune modulation without immune suppression



**Decrease systemic and local inflammation**

**Decreases liver inflammation - Improves liver function**

# IMM-124E In NASH

**Fibrotic Liver**



**IMM-124E**

**IMM-124E Treated Liver**




Mizrahi M. 2013, AASLD; Hepatology 751A





# IMM-124E - Improves Inflammation and Fibrosis Markers


Immuron



Decreased Portal Inflammation




Improved Metavir Fibrosis Score




# IMM-124E Clinical Improves Liver Function and Insulin Resistance

Results of a Phase I/IIA clinical trial; N=10

## Improved Liver Enzymes



## Improved HbA1C, OGTT and HOMA



## NASH – A \$35B - \$40B Market Major Commercial Opportunity

- 25% of the US population has NAFLD
- 5% of the population will develop NASH
- No treatments approved
- All major pharma looking to get into the game
- Most treatments
  - Do not capture the entire disease population
  - Limited efficacy
  - Severe / unknown side effect profile

**Estimated Market Size: \$35B - \$40B USD by 2025 (Deutsche Bank)**




## PORTFOLIO

- IMM-124E (anti LPS + adjuvants) for NASH
- **IMM-529 for Clostridium Difficile**

# C-Difficile – A Significant Unmet Need


Center for Disease Control (CDC)  
Antibiotic Resistance Threats in the United States, 2013




## IMM-529 – Toxin B Vaccine Specially Developed to Defeat C-Diff

- IMM-529 is combination vaccine that targets: Toxin B, C-Diff spores and C-Diff vegetative cells
- Murine studies performed at Monash University, Australia:
  - Prophylaxis – Demonstrating effectiveness in 80% of cases
  - Treatment – Prevented death in 80% of cases

### Prophylaxis



### Treatment





A blue-tinted illustration of a human torso from the neck down to the waist. The skin is semi-transparent, revealing internal organs including the lungs, heart, liver, stomach, and a detailed, glowing red and yellow large intestine. The background is a solid blue gradient.

Immuron

TRAVELAN®

Stop it before it starts

# Travelan® A Unique Preventative Product



The only therapy that prevents Travelers' Diarrhea by up to 90%

**Without Travelan®:**  
Bacteria attach to gut wall and infect



**With Travelan®:** Bacteria neutralized by Travelan® antibodies



- Marketed in the US, Australia by Immuron and by Paladin/Endo in Canada
- Global market estimate: US\$ 600M - 1.2B
- All-natural product;
- Clinically proven
- SAFE
- OTC
- Strong brand loyalty
- Multiple life-cycle opportunities



# Travelan®

———— Status 06/2015

————→ Progress in 07/2015 – 06/2016

Country	Discussions	Term Sheet	Licensed	Regulatory	In Market
Canada	————→				
South Korea	————→				
Other Asian Countries	————→				
United States	————→				
India	————→				
China	————→				

\* Regulatory application preceding partnering engagement

An anatomical illustration of a human torso from the waist up, rendered in a semi-transparent blue style. The internal organs are highlighted in warm colors: the liver is a solid reddish-brown, the lungs are a lighter, translucent blue, and the large and small intestines are shown in a complex, coiled pattern of red and orange. The background is a solid blue gradient.

Immuron

# SUMMARY



# Investment Highlights

## Immuron Is a Compelling Investment Opportunity

---

NASH and ASH:	Two Phase II studies in progress with an increasingly alluring potential upside
Travelan:	Revenues growing and positioned to grow further with successful USA launch
Pipeline:	Progressing; potential for multi-billion \$ assets
Cap Profile:	Robust
Financials:	Debt free, cash in the bank until after completion of NASH trial

---

# Corporate Structure

## The Board and Management

Dr Roger Aston  
**Chairman**

Roger has more than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding Chief Executive Officer and a Director of Mayne Pharma Group Limited.

Daniel Pollock  
**Non-executive Director**

Daniel is an internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in overseas new market entries, distribution agreements and corporate start-ups.

Stephen Anastasiou  
**Non-executive Director**

Stephen has extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG.

Thomas Liquard  
**Chief Executive Officer**

Thomas spent the majority of his career at Pfizer in New York in various commercial positions and was COO then CEO of Alchemia Limited, an oncology ASX biotech company.

Dan Peres, MD  
**Head of Medical**

Dan had been leading Medical Device and Pharma companies in their clinical stage since 2008. a Physician in origin has years of experience in management and medical development.

Jerry Kanellos, PhD  
**COO & Scientific Officer**

Dr Jerry Kanellos has over 20 years of experience in the pharmaceutical and biotech industries including CMC, operations and business development. He has held senior roles at CSL and Transbio Limited.

Neta Tobis  
**Clinical Director**

With over 7 years' experience of international trial management for small to large pharma and medical device companies as well as working within large CROs (PPD).

Reza Moussakhani  
**Manufacturing Quality Director**

A professional Operations manager with extensive experience in implementation of project / quality and process improvements including with Hospira and Sigma Pharmaceuticals.

Dr. Yaron Ilan  
**Medical and Scientific Advisor**

Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Immuron

THANK YOU

